If this message does not display properly, please click here to launch your browser.
| Rheumatoid Arthritis: Will Actemra Ultimately Steal Market Share from the TNF-Alpha Inhibitors? Based on our Pharmacor advisory service entitled Rheumatoid Arthritis, Decision Resources is offering an exclusive analyst call entitled Rheumatoid Arthritis: Will Actemra Ultimately Steal Market Share from the TNF-Alpha Inhibitors? Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. Earlier this month, the U.S. Food and Drug Administration approved Genentech/Roche's Actemra for use in adults with moderate to severe rheumatoid arthritis who have had an inadequate response to other therapies. As a result, rheumatoid arthritis is now the first approved indication for Actemra in the U.S. Actemra will benefit from a strong efficacy profile and a fast onset of action and, as previously forecasted by Decision Resources, the agent will achieve blockbuster sales in 2018. Additionally, Actemra’s U.S. launch not only further fragments the rheumatoid arthritis biologics landscape but presents a formidable challenger to Bristol-Myers Squibb’s Orencia and Genentech/Roche’s Rituxan and, ultimately, Actemra could erode share of the TNF-alpha inhibitors. This 15-minute analyst call, presented by Analyst Kyle Crowell, will answer the following questions:
Mr. Crowell will conduct a live Q & A session after the presentation. Registration Rheumatoid Arthritis: Will Actemra Ultimately Steal Market Share from the TNF-Alpha Inhibitors? February 10, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Kyle Crowell is a research associate in the Immune and Inflammatory Disorders department of Decision Resources. Mr. Crowell, who joined the company in 2008, has co-authored reports on inflammatory disorders including rheumatoid arthritis, ulcerative colitis, Crohn’s disease and atopic dermatitis. Mr. Crowell earned a B.S. in Biochemistry from Boston College.